Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium

Award Number: UG1CA242609
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium - Cancer is second cause of death in the United States. Cancer prevention strategies represent the most promising means by which to reduce cancer-related deaths and cancer incidence. Feasibility of vaccines and cancer prevention drugs has been demonstrated in clinical trials targeting the prevention of cancer (recently renamed as ‘Cancer Interception'). Unfortunately, side effects associated with the use of these agents has limited their use. Therefore, there is an urgent need for more effective and less toxic cancer prevention interventions that healthy individuals would deem as both beneficial and tolerable. Our overarching goal is to continue developing the next wave of cancer interception agents by engaging our expert team of researchers to: 1. identify and develop novel effective and tolerable cancer interception strategies; 2. test the most promising of those strategies in early-phase cancer prevention clinical trials; and 3. translate these therapies to the clinic for individuals at high-risk of cancer. To this end, the MD Anderson “iCAN PREVENT” Consortium has renewed its commitment to cancer interception by bringing additional world leaders in cancer prevention, novel concepts for future clinical trials, updating our cores with state-of-the-art technologies (spatial transcriptomics, single-cell genomics), incorporating novel approaches to recruit and retain participants and incorporating a council of patient advocates combined with our pathology, systems biology, and statistics experts, to collaborate in the development of novel early-phase cancer interception clinical trials. With over 30 Phase I and II prevention trials conducted through our previous MD Anderson clinical trial consortia, our team brings knowledge and experience in the development and conduction of clinical trials while we incorporate novel ideas from junior investigators and new trial sites. To continue supporting these clinical trials, we focus on two aims: 1. testing the safety and efficacy of cancer prevention drugs, vaccines, and immune modulating interventions in individuals at high-risk for cancer development in >5 early-phase prevention trials; and 2. implementing the most novel methods to enhance recruitment and retention of participants to our trials. Included in this application are two sample trials: 1. a Phase II study testing low-dose enzalutamide for prostate cancer prevention in men with low-risk prostate cancer who are under active surveillance; and 2. a Phase II study comparing the efficacy of aerobic exercise, naproxen or the combination of both to modulate the immune system for cancer prevention in Lynch syndrome carriers. In addition, we present several potential concepts to be developed by our consortium. The results of our previous preventive studies have demonstrated that we are leaders developing new cancer interception strategies, which would provide the foundation to advance these interventions to Phase III with the ultimate goal of FDA-approval.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Control	001	7	6/9/2026	COMPETING CONTINUATION	$0
2026	2024	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	6	1/2/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,627,502 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Control	001	7	8/4/2025	COMPETING CONTINUATION	$1,627,502
2025	2024	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	6	1/15/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,627,502

Issue Date FY: 2024 ( Subtotal = $1,321,621 )
2024	2024	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	6	8/19/2024	NON-COMPETING CONTINUATION	$1,321,621
														Subtotal = $1,321,621

Issue Date FY: 2023 ( Subtotal = $1,363,358 )
2023	2023	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	5	9/7/2023	NON-COMPETING CONTINUATION	$0
2023	2023	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	5	8/25/2023	NON-COMPETING CONTINUATION	$1,363,358
														Subtotal = $1,363,358

Issue Date FY: 2022 ( Subtotal = $911,328 )
2022	2022	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	4	8/18/2022	NON-COMPETING CONTINUATION	$911,328
														Subtotal = $911,328

Issue Date FY: 2021 ( Subtotal = $1,822,363 )
2021	2021	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	3	8/17/2021	NON-COMPETING CONTINUATION	$1,822,363
														Subtotal = $1,822,363

Issue Date FY: 2020 ( Subtotal = $1,814,563 )
2020	2020	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	2	8/21/2020	NON-COMPETING CONTINUATION	$0
2020	2020	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	2	8/13/2020	NON-COMPETING CONTINUATION	$1,814,563
														Subtotal = $1,814,563

Issue Date FY: 2019 ( Subtotal = $947,195 )
2019	2019	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	1	8/15/2019	NEW	$947,195
2019	2019	UNIVERSITY OF TEXAS M D ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD UNIT 207	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	1	8/19/2019	NEW	$0
														Subtotal = $947,195

Grand Total All Awards = $9,807,930

Top

All Categories

About

Search

Reports

Data Submission

Award Information

iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium

Award Number: UG1CA242609

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer